Key Takeaways for DSO vs. Private Sales
- DSO buyers can pay higher EBITDA multiples than private buyers, but they first reduce EBITDA for market-rate associate compensation, which creates a more nuanced comparison.
- DSO deals typically deliver 60–80% of total value in cash at close with an equity rollover, while private sales more often provide 80–100% cash at closing with shorter work-back periods.
- Equity rollover in DSO transactions carries meaningful risk because it depends on platform performance and is usually illiquid for 4–7 years until a future exit.
- DSO affiliations usually require several years of post-close clinical employment with lower compensation percentages than owner economics, while private sales often involve only brief transition periods.
- McLerran & Associates provides side-by-side valuations and runs competitive processes that help sellers improve outcomes, so schedule a free discovery call to review your options.
Key Tradeoffs for Dental Practice Sellers
- Valuation ceiling: DSO buyers can pay higher EBITDA multiples than individual buyers, but they apply those multiples to EBITDA that has been adjusted downward for market-rate associate compensation.
- Cash at close: DSO deals typically deliver 60–80% of total consideration in cash, while private sales are more likely to deliver 80–100% of the price at closing.
- Equity rollover risk: A meaningful portion of a DSO deal can be paid in equity that stays illiquid until a future platform exit, typically 4–7 years away.
- Work-back period: DSO affiliations commonly require several years of post-close clinical employment, while private-buyer walk-away sales often require only weeks of transition.
- Post-sale compensation: After affiliating, selling dentists usually earn a lower percentage of collections as employed clinicians than they retained as owners.
- Close probability: Competitive, advisor-run processes tend to close at much higher rates than do-it-yourself negotiations, and McLerran & Associates reports a high transaction rate compared with an industry norm closer to 35–40%.
Schedule a free, confidential discovery call with McLerran & Associates to receive a side-by-side valuation of your practice in both markets before you decide.
Comparing DSO and Private Buyer Sales
The two pathways differ across nearly every dimension of a transaction. Private-buyer transactions are more likely to pay the seller in full at closing, assuming lender approval and clean practice fundamentals, and they usually involve a shorter and more flexible transition period. DSO deals introduce layered complexity with cash, equity, and earnouts, and each component carries its own risk profile and tax treatment.
Platform DSOs and portfolio DSOs have competed aggressively since 2018 for mid-career practices with $1.5 M or more in collections, and they often offer cash multiples above traditional benchmarks on high-EBITDA practices. That competition becomes meaningful only when multiple buyers are at the table. A seller who approaches a single DSO directly negotiates without leverage against a buyer that structures deals every week.
McLerran & Associates runs both pathways in roughly equal measure, with approximately a 50/50 split between private-buyer and DSO transactions. Clients receive a genuine side-by-side comparison instead of a recommendation shaped by whichever path the advisor happens to know best.
How DSOs Use EBITDA to Price Practices
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. In practical terms, it measures a practice’s operating profitability after removing personal, discretionary, and non-recurring expenses, but before financing costs or accounting adjustments. DSO buyers apply a multiple to this number to arrive at an enterprise value.
DSO buyers make a critical adjustment by replacing the owner’s reported compensation with a market-rate go-forward compensation number, usually a percentage of net collections for general dentistry. This adjustment is often the single largest pro forma change and can move final valuation by hundreds of thousands of dollars. A practice where the owner takes home $600,000 but a replacement associate would cost $350,000 has a meaningfully higher adjusted EBITDA, and therefore a higher DSO valuation, than the owner’s tax return alone would suggest.
Dental practices sell within a range of multiples of adjusted EBITDA. The multiple can be influenced by practice size, EBITDA margin, scalability, hygiene revenue as a percentage of collections, provider dependence, and the buyer’s strategic rationale. Individual buyers typically pay a percentage of annual collections, while DSO offers can equate to a higher percentage of collections for larger practices with strong associate leverage.
Specialty practices can command different multiple ranges than general dentistry, and the spread between specialties can be meaningful. However, the factors that can move any practice toward the top of its range tend to be consistent, including EBITDA margin above 18–25%, hygiene revenue above 30% of collections, multi-doctor staffing, and limited owner-production dependence.
Typical DSO Work-Back Timelines
DSOs are more consistently requiring a minimum post-close employment term and often cite provider risk and clinical continuity as top reasons for terminating deals. In practice, many DSO affiliations require several years of continued clinical work as an employed dentist.
During that period, the selling dentist shifts from retaining full practice profits to earning a production-based salary. Post-sale DSO compensation is usually structured as a salary, sometimes as base pay plus a percentage of collections above a threshold. That structure often represents a meaningful reduction from owner economics for many premier practice owners, and it belongs in any honest after-tax cash-flow comparison.
Private-buyer walk-away sales typically require only a short work-back period before the seller exits entirely. A partnership or vest-out structure, where the seller transfers roughly 50% now and the remainder over time, extends the timeline but preserves income during the transition.
Risks of DSO Equity Rollovers
Equity rollover, which is the portion of deal proceeds paid in DSO stock rather than cash, is effectively mandatory in most DSO structures. DSO transactions usually include a meaningful equity rollover for selling dentists, and that equity participates in a later platform exit that often occurs 4–7 years after closing.
These risks are specific and can be significant. DSO equity rollover depends on the parent company’s success, the terms of preferred versus common equity, and future recapitalization timelines. Sellers are often well served by obtaining independent legal review of equity documents instead of relying only on the DSO’s counsel. The ultimate payout can depend on platform performance, liquidation preferences, current leverage, and the timing of the next recapitalization or sale, and the selling dentist does not control those factors after closing.
Equity held at the joint-venture level, which is tied to a specific practice, typically provides distributions and a higher floor but a lower ceiling. Equity held at the holding-company level provides no distributions but can multiply several times at a platform exit if the platform performs well. McLerran & Associates helps clients review a DSO’s profitability, growth trajectory, management team, and financial backing before any equity commitment and steers clients away from undercapitalized buyers.
When DSO Sales Fit by Practice Size
Practice size and EBITDA can be some of the main filters for deciding which path may serve a given owner. The following decision framework reflects general market dynamics as of 2026, and individual circumstances vary, so a side-by-side valuation remains the most reliable way to confirm which path fits your practice.
- Under $1 M in annual revenue: The private-buyer, doctor-to-doctor path is usually the stronger fit. DSO interest at this size tends to be limited, and individual buyers financed through conventional lending can be competitive.
- $1–1.5 M in annual revenue: This range is primarily a private-buyer market, though select DSOs may express interest depending on geography, specialty, and EBITDA margin. A side-by-side valuation can clarify whether DSO interest is meaningful.
- $1.5–3 M in annual revenue: Both paths are genuinely available in this “Venn diagram” middle. The economic comparison matters most here, and the difference between a competitive process and a single-buyer negotiation can reach hundreds of thousands of dollars.
- $3 M+ in annual revenue: DSO and private equity buyers are typically the primary market. The practice may be too large for a single-doctor buyer to finance, and DSO multiples at this size can be materially higher.
- $2.5 M+ in EBITDA: The practice may qualify as a platform acquisition, which is the founding asset of a new DSO, and the owner may step in as its CEO and access some of the highest available multiples.
- Owner within 3 years of full retirement: A full buyout structure with higher cash at close and no retained equity may be preferable to a joint-venture rollover that requires a longer time horizon to realize equity value.
- Owner 10–20 years from retirement: A joint-venture or equity-rollover structure may provide meaningful upside through a future platform exit, provided the DSO is well-vetted.
Side-by-Side Deal Structure Comparison
| Dimension | Private Buyer (Doctor-to-Doctor) | DSO / Private Equity Affiliation |
|---|---|---|
| Valuation method | A percentage of trailing 12-month collections, or a multiple of adjusted EBITDA for solo practices | A multiple of adjusted EBITDA depending on size, margin, and buyer type, with EBITDA adjusted for market-rate associate compensation |
| Cash at close | Typically 80–100% cash at close, with some seller note and no equity rollover | Typically 60–80% cash at close, with some equity rollover |
| Work-back period | A few weeks for a walk-away sale, or 1–3 years for a partnership or vest-out | Several years of post-close clinical employment, with minimum 5-year terms increasingly common |
| Post-sale income | Full exit after work-back, with no ongoing compensation dependence on the practice | A percentage of collections as an employed clinician, versus a higher percentage retained as an owner |
| Transaction close rate (advisor-run) | A high percentage with a well-run brokered process, and a low percentage for do-it-yourself sales | A high percentage with McLerran’s structured bid process, compared with a lower industry norm |
| Competitive process timeline | Typically 60–120 days to close with a qualified buyer pool | Several months from initial conversation to wire, with McLerran’s bid process usually 45–60 days to generate multiple offers |
After-Tax Cash-Flow Modeling Over Time
The table below offers a directional framework for comparing after-tax cash flow across the two pathways for a hypothetical $2 M revenue general dental practice with a 25% EBITDA margin, or $500,000 of adjusted EBITDA. These figures are illustrative only and do not guarantee any specific outcome. Actual results depend on your practice’s financials, deal structure, tax situation, and DSO performance, so consult your CPA and legal counsel before making decisions.
| Scenario | Year 3 Cumulative (Illustrative) | Year 5 Cumulative (Illustrative) | Year 7–10 Cumulative (Illustrative) |
|---|---|---|---|
| Private buyer — walk-away sale (cash at close represents most of deal value, with no ongoing equity risk and a short work-back) | Full proceeds received at close with no earnout dependence, and after-tax outcome driven largely by long-term capital gains on goodwill | Proceeds invested or deployed, with no post-sale income from the practice and a clean exit with no platform risk | No additional upside from the practice, and total outcome fixed at close |
| DSO affiliation — full buyout (most value in cash at close, a percentage of collections as employed clinician, and an earnout tied to EBITDA targets) | Cash at close plus 3 years of employed compensation, with earnout at risk if EBITDA targets are missed and annual income often lower than pre-sale owner economics | Employment term usually complete and earnout resolved, and total cash-in-hand may exceed private-buyer outcome if the headline multiple was materially higher | No residual equity upside in a full-buyout structure, and total outcome fixed at the end of the employment term |
| DSO affiliation — joint-venture / equity rollover (most value in cash at close, some retained equity, and potential second exit at recapitalization) | Partial cash at close plus employed compensation, with equity illiquid and distributions possible at the joint-venture level | Equity begins to mature toward the recapitalization window, and an equity stake can potentially grow at a platform exit, though outcome is not guaranteed | Second exit realized if the platform recapitalizes, and total outcome can exceed the private-buyer path or fall short if the platform underperforms, which creates the highest variance of all structures |
McLerran & Associates produces multi-year, multi-structure financial forecasting for every client, modeling real after-tax proceeds across deal structures and time horizons so the comparison rests on actual numbers rather than headline multiples.
Understanding Your Practice’s Market Value
The first step in any transition is knowing what your practice may be worth in both markets. A $50,000 improvement in EBITDA can add $250,000 or more to a dental practice’s sale value, while a $200,000 improvement can add $1,000,000 or more, depending on the multiple applied. That math can make valuation quality one of the most consequential inputs in the entire process.
Because valuation quality matters so much, McLerran & Associates builds a CPA-led, diligence-grade EBITDA analysis for every engagement, reviewing discretionary, personal, and non-recurring expenses to arrive at true profitability. That number is then tested against both the private-buyer and DSO markets, which gives owners a genuine side-by-side comparison before any path is chosen. Because timing can be as important as accuracy, if you are not ready to sell, McLerran will update the valuation for free a year later rather than push you into a deal.
Schedule a free, confidential discovery call with McLerran & Associates to find out what your practice may be worth in both markets, with no obligation to proceed.
Creating Competition Among Buyers
About 69% of DSOs surveyed expect their private equity sponsors to drive a moderate or high increase in 2026 acquisition activity, and 78% of DSO buyers anticipate recapitalization within 12–36 months, which can create real leverage for sellers who enter the market with a competitive process. Demand for premier, Class A practices remains strong, and valuations sit near all-time highs for well-documented, high-margin practices.
McLerran & Associates runs a structured, auction-like bid process that usually lasts 45–60 days and often generates around 10 offers from a vetted pool of well-qualified buyers. Poorly run or undercapitalized buyers are removed before the process begins. Clients typically receive approximately a 30% increase in valuation compared with selling alone, and the competitive tension can help hold the agreed value through diligence instead of allowing it to be negotiated downward.
Finding the Right Buyer Fit
The highest bidder does not always deliver the strongest outcome. A higher enterprise value offer can produce lower seller proceeds than a lower headline offer if it includes greater rollover equity, larger holdbacks, tighter working-capital targets, or longer employment terms. Evaluating fit often requires looking past the headline number to the full structure, the buyer’s track record with previously acquired practices, and the post-close environment for staff and patients.
McLerran & Associates narrows a field of approximately 10 initial offers to in-person meetings with the top one to three finalists and vets each buyer’s profitability, growth, leadership, and financial backing. The firm’s mandate is to balance price and fit, securing a strong financial outcome while identifying a buyer whose strategy and support model can protect the legacy, patients, and staff the seller leaves behind.
Protecting and Maximizing Your Outcome
Maximizing outcome often starts with controlling the narrative around your EBITDA from the first conversation through the final wire. Dental practices that complete a quality-of-earnings review before going to market can achieve 20–40% higher final sale outcomes by increasing buyer confidence and reducing renegotiation risk during due diligence. Without that preparation, a buyer’s diligence team can set the narrative, and the agreed value can erode.
McLerran & Associates provides quality-of-earnings support during diligence on DSO deals, defending the EBITDA it underwrote when the buyer’s team reviews add-backs and reminding buyers that other vetted bidders remain available if they attempt to re-trade the deal. Across roughly 2,000 successful practice sales and approximately $2 billion in closed transaction volume, the firm’s ~85–90% transaction rate reflects a process designed to close, not just to list.
Schedule a free, confidential discovery call with McLerran & Associates and place a sell-side advocate in your corner before the first DSO conversation begins.
Frequently Asked Questions
How do DSOs make money?
DSOs generate revenue in two main ways. First, they capture the spread between what a dental practice earns under independent ownership and what it earns under centralized management. By reducing costs in areas such as supplies, staffing, billing, and compliance through economies of scale, the DSO can improve the practice’s EBITDA margin and retain that improvement as profit.
Second, DSOs are typically backed by private equity, which means the DSO itself is built to be sold. When the private equity sponsor exits, usually through a recapitalization or sale to a larger platform, the DSO is valued at a multiple of its aggregate EBITDA across all affiliated practices. That exit multiple is often higher than the multiples paid to individual practice sellers, and this spread is the source of the equity rollover upside that selling dentists receive as part of their deal structure. Understanding this model can help any dentist evaluating a DSO affiliation, because you are not just selling a practice, you are also becoming a minority investor in a platform built for a future exit.
How much does a successful dental practice sell for?
The sale price of a dental practice can depend on revenue, EBITDA margin, specialty, buyer type, and the competitiveness of the sale process. In the current market, practices sold to individual buyers usually transact at a percentage of trailing collections or at a lower EBITDA multiple, while DSO buyers apply higher multiples to adjusted EBITDA, with the range varying based on practice size, scalability, and the buyer’s strategic rationale.
Specialty practices can command different ranges than general dentistry. The most reliable way to estimate what your specific practice may be worth is a CPA-led, diligence-grade EBITDA analysis that accounts for your actual add-backs, payer mix, provider dependence, and market, rather than a quick estimate from a buyer. McLerran & Associates has evaluated more than 10,000 dental practices and can quantify your potential value in both the private-buyer and DSO markets before you commit to any path.
How do you sell a dental practice to a DSO?
Selling to a DSO usually involves several phases. These include preparing a diligence-grade EBITDA analysis and marketing package, identifying and approaching qualified DSO buyers, running a competitive bid process to generate multiple offers, and negotiating the letter of intent that covers cash at close, equity structure, earnout terms, and the employment agreement. The process then moves into due diligence and closing.
The most common mistake many sellers make is approaching a single DSO directly, which removes competitive tension and gives the buyer full control of the valuation narrative. A well-run sell-side process can create competition among multiple vetted buyers, defend the agreed EBITDA through diligence, and negotiate deal terms that protect the seller’s interests across all three roles they play in a DSO transaction: seller, future partner, and equity investor. McLerran & Associates manages this process on the seller’s behalf from valuation through closing.
Is it hard to sell a dental practice?
Selling a dental practice can be one of the most complex financial transactions many dentists will ever complete, and the process can be more fragile than many sellers expect. Do-it-yourself close rates can run as low as 15–20%, while a well-run brokered process can close at around 80%.
Deals often fall apart because of weak or undefended valuations that get renegotiated in diligence, associate retention issues that trigger earnout reductions, lease problems, or a failure to maintain confidentiality during the process. Complexity can increase in DSO deals, where the structure includes multiple components such as cash, equity, and earnouts, and each component carries different risk profiles and tax treatment. Working with a dental-specific sell-side advisor who has navigated many of these transactions can improve both the probability of closing and the outcome at close.
What is the 2-year rule for dentists?
The “2-year rule” often refers to the minimum post-close employment period that some DSO buyers require as a condition of the acquisition. The idea is that the selling dentist remains clinically active for at least 2 years to support patient and revenue continuity after the transition.
In practice, this standard has shifted. Many DSOs now require 3–5 years of post-close clinical employment, and minimum 5-year terms are becoming more common as buyers focus on provider retention and clinical continuity. The length and terms of the employment agreement, including compensation structure, non-compete geography and duration, and clinical autonomy provisions, can be some of the most important elements to negotiate in any DSO deal. A shorter work-back may be possible if the seller has already reduced clinical production and the practice has strong associate coverage, but this outcome requires negotiation and is not guaranteed.
Do most dentists become millionaires?
Dentistry ranks among the higher-earning professions in the United States, and practice ownership, especially of a premier, high-producing practice, can generate substantial wealth over a career. The transition event itself can be a significant wealth-creation moment. A well-run competitive sale of a $1.5–3 M revenue practice can produce proceeds that, combined with a career of practice distributions, place many dentists in seven-figure net worth territory.
Outcomes can depend heavily on how the sale is structured and executed. A seller who negotiates alone against a sophisticated DSO buyer, or who accepts the first offer without creating competition, may leave hundreds of thousands of dollars or more on the table. The difference between a well-advised sale and an unadvised one can become one of the largest financial decisions of a dentist’s career. McLerran & Associates clients typically receive approximately 30% higher valuations than owners achieve selling on their own, a pattern that has been consistent across the firm’s transaction history.
Conclusion: Applying This Evaluation Framework
For owners of $1.5–3 M revenue dental practices, the choice between a DSO affiliation and a private-buyer sale often goes beyond headline numbers. It can be a multi-year economic decision that turns on EBITDA mechanics, equity risk, post-sale compensation, tax treatment, work-back commitments, and buyer quality, all measured against your goals for legacy, staff, and personal wealth.
The market in 2026 remains active. The U.S. dental industry continues to consolidate, DSO acquisition activity is accelerating, and valuations for premier practices remain near all-time highs. Expiring tax provisions in 2026 are creating urgency among some mid-career sellers to transact before rates change. The window for owners of high-quality practices can be attractive, provided the process is run carefully.
McLerran & Associates is a dental-only sell-side advisor with the track record described throughout this article. The firm works both pathways in roughly equal measure, produces a genuine side-by-side valuation for every client, and runs a structured competitive process that often generates around 10 offers and can lift valuations well above what many owners achieve alone. The firm never represents the buyer, so its incentives stay aligned with the selling dentist from first conversation to final wire.
If you are considering a transition now or in the future, schedule a free, confidential discovery call with McLerran & Associates. Call (512) 900-7989, email info@dentaltransitions.com, or visit dentaltransitions.com.
